The losartan renal protection study — rationale,study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
Restricted accessOtherFirst published online December, 2000
The losartan renal protection study — rationale,study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients must have a urinary albumin:creatinine ratio of at least 300 mg/g and serum creatinine between 1.3 to 3.0 mg/dL. Eligible hypertensive or normotensive patients are randomised to receive either losartan or placebo, in addition to their existing antihypertensive therapy. Medications that block angiotensin production or action, are excluded. The primary endpoint is a composite of the time to first event of doubling of serum creatinine, end-stage renal disease, or death; secondary endpoints include cardiovascular events, progression of renal disease, and changes in proteinuria; tertiary endpoints include quality of life, healthcare resource utilisation, and amputations. Patients include Caucasians (48.6%), Blacks (15.2%), Asians (16.7%), and Hispanics (18.2%). Baseline urinary albumin:creatinine ratio and serum creatinine levels average 1867 mg/g and 1.9 mg/dL, respectively. Mean systolic and diastolic blood pressures are 153 and 82 mmHg, respectively. RENAAL will document whether blockade of the AII receptor with losartan produces clinical benefits in patients with Type 2 diabetes and nephropathy.
USRDS: Annual Data Report, Chapter 2. Incidence and prevalence of ESRD. Am J Kid Dis1999;34(suppl 1):S40-S50.
2.
Ritz E., Keller CK, Bergis KH, Siebels M.Renal involvement in type II diabetes. Curr Opin Nephrol Hypertens1994;3:137-44.
3.
Bennett PH, Haffner S., Kasiske BL et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the council on diabetes mellitus of the National Kidney Foundation. Am J Kidney Dis1995;25:107-12.
4.
Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJChronic renal failure in non-insulin dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med1989;111:788-96.
5.
Cordonnier DJ , Zmirou D., Benhamou P-Y., Halimi S., Ledoux F., Guiserix J.Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetes mellitus. The case of mainland France and of overseas French territories . Diabetologia1993;36:1109-12.
6.
Zmirou D., Benhamou P-Y., Cordonnier D. et al. Diabetes mellitus prevalence among dialysed patients in France (URE-MIDIAB Study). Nephrol Dial Transplant1992;7:1092-7.
7.
Rettig B.,Teutsch SMThe incidence of end-stage renal disease in type I and type II diabetes mellitus . Diabetic Nephrop1984;3:26-7.
8.
Pugh JA, Medina RA, Cornell JC, Basu S.NIDDM is the major cause of diabetic end-stage renal disease. More evidence for a tri-ethnic community. Diabetes1995;44:1375-80.
9.
USRDS:Annual Data Report. Chapter 5. Patient mortality and survival . 1995;pp59-77.
10.
USRDS:Annual Data Report. Chapter 7. Renal transplantation: access and outcomes. 1995;pp91-108.
11.
Lafayette RA , Mayer G., Park SK, Meyer TWAngiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass . J Clin Invest1992;90:766-71.
12.
Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJAngiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther1993 ;267:657-63.
13.
Remuzzi A., Perico N., Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol1993;4:40-9.
14.
Kohzuki M., Yasujima M., Kanazawa M. et al. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertension1995;13:97-103.
15.
Owen RA, Molon-Noblot S., Dorian C. et al. Long-term effects of treatment with losartan [AT1-selective angiotensin II (AII) receptor antagonist] on renal function and structure in streptozotocin (STZ)-induced diabetic nephropathy. J Am Soc Nephrol1995;6:880 (abstract).
16.
Gansevoort RT , de Zeeuw D., de Jong PEIs the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system. Kid Intl1994;45:861-7.
17.
Gansevoort RT , de Zeeuw D., Shahinfar S., Redfield A., de Jong PEEffects of the angiotensin II antagonist losartan in hypertensive patients with renal disease . J Hypertension1994;12 (suppl 2):S37-S42.
18.
Holdaas H., Hartmann A., Berg KJ, Lund K., Fauchald P.Renal protective effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant1998;13:3096-102.
19.
Del Castillo D., Campistol JM, Guirado L. et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant patients . Kidney Int1998;54 (suppl 68):S135-S139.
20.
Mitch WE, Walser M., Buffington GA, Lemann J. Jr.A simple method of estimating progression of chronic renal failure. Lancet1976;2:1326-8.
21.
Ware JE, Sherbourne CDThe MOS 36-item Short Form Health Survey (SF-36). I conceptual framework and item selection. Med Care1992;30:473-83.
22.
EuroQual Group: EuroQual-a new facility for the measurement of health-related quality of life. Health Policy1990;16:199-208.
23.
Amos AF, McCarthy DJ, Zimmet P.The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med1997;14:S7-S85.
24.
Zeller K., Whittaker E., Sullivan L., Raskin P., Jacobson HREffect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med1991;324:78-84.
25.
Raal FJ, Kalk WJ, Lawson M. et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-month prospective study. Am J Clin Nutr1994;60:579-85.
26.
Diabetes Control and Complications Trial: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977-86.
27.
Kawazu S., Tomono S., Shimizu M. et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. J Diab Comp994;8:13-17.
28.
Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract1995;28:103-17.
29.
Parving HH,AndersenAR,Smidt UM, Hommel E., Mathiesen ER, Svendsen PAEffect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J1987;294: 1443-7.
30.
Rossing P., Hommel E., Smidt UM, Parving HHReduction in albuminuria predicts diminished progression in diabetic nephropathy . Kidney Intl1994;45(suppl 45):S145-S149.
31.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J1998 ;317: 703-13.
32.
Hansson L., Zanchetti A., Carruthers SG et al., for the HOT Study Group.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet1998;351:1755-62.
33.
Bjorck S., Mulec H., Johnsen SA, Norden G.,Aurell M.Renal protective effect of enalapril in diabetic nephropathy. Br Med J1992;304:339-43.
34.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting enzyme inhibition on diabetic nephropathy .NEnglJMed1993;329:1456-2.
35.
Ravid M., Savin H.,Jutrin I., BentalT,Katz B., Lishner M.Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med1993;118:577-81.
36.
Ahmad J., Siddiqui M.,Ahmad H.Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care1997;20:1576-81.
37.
UK Prospective Diabetes Study Group.Effect of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J1998;317:713-20.
38.
Goldberg AI , Dunlay MC, Sweet CSSafety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with HCTZ, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol1995;75:793-5.
39.
Weir MR, Elkins M., Liss C.,Vrecenak AJ,Barr E., Edelman JMEfficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Therapeut1996;18:411-28.
40.
Oparil S., Barr E., Elkins M., Liss C., Vrecenak A., Edelman J.Efficacy, tolerability, and effects on quality of life of losartan, alone or with HCTZ, versus amlodipine, alone or with HCTZ, in patients with essential hypertension. Clin Therapeut1996 ; 18:608-25.
41.
Lacourcière Y., Brunner H., Irwin R. et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertension1994;12:1387-93.
42.
Toto R., Shultz P., Raij L. et al., for the Collaborative Group.Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension1998;31:684-91.
43.
Sica DA, Lo M-W., Shaw WC et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens1995;13(suppl 1):S49-S52.
44.
Saracho R., Martin-Malo A., Martinez I.,Aljama P., Montenegro J.Evaluation of losartan in hemodialysis (ELHE) study. Kidney Intl1998;54(suppl 68):S125-S129.
45.
Ragonesi PD , Belviso A.,Tarata C., Taddei MTThe effects of angiotensin II antagonist losartan on urinary albumin excretion in non-insulin dependent diabetes mellitus. Am J Hypertens1998;11(4 part 2):47 abstract.
46.
Lacourcière Y. , Bèlanger A., Godin C. et al. Comparison of the long-term effects of losartan and enalapril on urinary albumin excretion (UAE) and glomerular filtration rate (GFR) in hypertensive subjects with type 2 diabetes and microalbuminuria . Submitted for presentation at the European Association for the Study of Diabetes, Belgium, September, 1999:1536 (abstract).
47.
Hansson L., Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet1999;353:611-6.
48.
Hansson L., Lindholm LH, Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6.
49.
The GISEN Group.Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy . Lancet1997;349:1857-63.
50.
The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEnglJMed2000;342:145-53.
51.
Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens1996;9:342-60. 52. National Institutes of Health News Release: NHLBI stops part of study-high blood pressure drug performs no better than standard treatment. March 8, 2000 .
52.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).JAMA2000;283:1967-75.
